This application proposes renewal of the UNC Breast Cancer SPORE. Originally funded in 1992, the UNC SPORE has used significant institutional investment and the distinctive SPORE elements: funding flexibility, interdisciplinary collaboration, bidirectional translational research, developmental programs, and interSPORE partners to build an outstanding program in translational breast cancer research. The UNC SPORE's combination of population-based research, molecular genetics, breast cancer biology, health disparities research, tissue-acquiring clinical trials, database development, and expertise in bioinformatics and biostatistics was made possible with long-term SPORE support. Interaction between disciplines has resulted in substantial productivity, as measured by important findings published in excellent journals, career advancement for junior investigators, developmental research leading to grants and new SPORE projects, multiple funded interSPORE collaborations, and innovative approaches to breast cancer etiology, classification, prognosis, and therapy. Our five projects are conceptually linked by studies of breast cancer molecular phenotypes, particularly those with the worst prognosis: basal-like tumors, luminal B tumors, and tumors that overexpress HER2. Led by basic and clinical science teams, these projects feature our continuing population science study, the Carolina Breast Cancer Study, and three translational clinical trials. Data from multiple national and international trials will also be incorporated into our analyses. The projects are entitled: 1) Carolina Breast Cancer Study: Genetic susceptibility for breast cancer subtypes in African Americans and whites 2) Breast cancer vaccine strategies for HER2 and luminal B tumors 3) Determination of breast cancer subtype sensitivities to standard chemotherapy and combination chemotherapy-biologic regimens 4) Molecular portraits of human breast cancer endothelium 5) HER4 Isoforms: Tumor suppressor action and prognostic significance They are supported by strong infrastructure and institutional commitment from the University of North Carolina, its UNC Lineberger Comprehensive Cancer Center, and its Schools of Medicine and Public Health. SPORE investigators will have access to Cancer Center core facilities as well as SPORE funded cores. Specific to the SPORE are Genomics, Genotyping & Bioinformatics, Tissue Procurement & Analysis, Biostatistics, and Administration

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-15
Application #
7291677
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Kuzmin, Igor A
Project Start
1997-08-05
Project End
2011-07-31
Budget Start
2007-09-19
Budget End
2008-07-31
Support Year
15
Fiscal Year
2007
Total Cost
$2,065,692
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications